Short answer
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed its Q2 2026 10-Q quarterly report on Jul 29, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $419M (up 0.8% year over year) with net income of $4M.
Q2 2026 key financials · XBRL
- Revenue
- $419M
- +0.8% YoY · +6.8% QoQ
- Net income
- $4M
- +100.9% YoY · +197.1% QoQ
- Operating margin
- 4.6%
- EPS (diluted)
- $0.06
- +100.9% YoY · +200.0% QoQ
Source: XBRL data from the INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Q2 2026 10-Q on SEC EDGAR. USD.
INTEGRA LIFESCIENCES HOLDINGS CORP Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Filing excerpt truncates after executive summary; quarterly revenue and YoY comparison unavailable
- Profitability margins and actual percentage changes unavailable in provided text
- Segment mix: Specialty Surgery approximately 70% of revenue; Tissue Reconstruction about 30%
- Braintree facility operational June 2026; SurgiMend relaunch planned fourth quarter 2026
- Cincinnati flooding caused operational disruptions; financial impact and insurance recoveries remain under assessment
Risk Factors
- No material changes to 10-K risk factors for year ended December 31, 2025
- Carried-forward regulatory and compliance risks remain unchanged from the 2025 10-K
- Carried-forward operational and competitive risks remain unchanged from the 2025 10-K
- Carried-forward liquidity, debt, currency, and concentration risks remain unchanged from the 2025 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other INTEGRA LIFESCIENCES HOLDINGS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.